Share on StockTwits
 

Gilead Sciences (NASDAQ:GILD) EVP Gregg H. Alton sold 120,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $80.00, for a total value of $9,600,000.00. Following the completion of the transaction, the executive vice president now directly owns 32,938 shares of the company’s stock, valued at approximately $2,635,040. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

GILD has been the subject of a number of recent research reports. Analysts at TheStreet reiterated a “positive” rating on shares of Gilead Sciences in a research note to investors on Wednesday, January 15th. Separately, analysts at Nomura initiated coverage on shares of Gilead Sciences in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Finally, analysts at UBS AG reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Monday, January 6th. They now have a $102.00 price target on the stock, up previously from $80.00. Two equities research analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and an average price target of $79.76.

Gilead Sciences (NASDAQ:GILD) traded up 0.74% during mid-day trading on Wednesday, hitting $82.18. 17,389,330 shares of the company’s stock traded hands. Gilead Sciences has a one year low of $38.545 and a one year high of $84.40. The stock’s 50-day moving average is $74.37 and its 200-day moving average is $66.18. The company has a market cap of $126.0 billion and a price-to-earnings ratio of 44.90. Gilead Sciences also was the target of unusually large options trading activity on Tuesday. Stock investors purchased 11,604 put options on the stock. This is an increase of approximately 131% compared to the typical daily volume of 5,028 put options.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the prior year, the company posted $1.00 earnings per share. The company’s quarterly revenue was up 14.7% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $2.00 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.